HIV Pharmacology: Barriers to the Eradication of HIV from the CNS
- 1 June 2006
- journal article
- review article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 7 (3) , 142-153
- https://doi.org/10.1310/aw2h-tp5c-np43-k6by
Abstract
Total eradication of HIV-1 is not yet achievable, in part because reservoirs of latent HIV-1 can develop within lymphoid tissue, the testes, and the central nervous system (CNS). The presence of HIV-1 in the CNS is clinically significant because of its association with the development of HIV dementia, which occurs in up to one fifth of untreated patients. This review summarizes current theory regarding HIV-1 infection within the CNS, describes physiologic and pharmacologic factors limiting CNS penetration of antiretroviral drugs used to treat HIV-1 infection, and reviews current treatment of CNS HIV-1 infection and HIV encephalopathy.Keywords
This publication has 64 references indexed in Scilit:
- Phylodynamic Analysis of Human Immunodeficiency Virus Type 1 in Distinct Brain Compartments Provides a Model for the Neuropathogenesis of AIDSJournal of Virology, 2005
- Zidovudine, Lamivudine, and Abacavir Have Different Effects on Resting Cells Infected with Human Immunodeficiency Virus In VitroAntimicrobial Agents and Chemotherapy, 2004
- The blood brain barrier in HIV infectionFrontiers in Bioscience-Landmark, 2004
- Genetic Characterization of Rebounding Human Immunodeficiency Virus Type 1 in Plasma during Multiple Interruptions of Highly Active Antiretroviral TherapyJournal of Virology, 2003
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Cerebrospinal Fluid Human Immunodeficiency Virus Type 1 (HIV‐1) Suppression and Efavirenz Drug Concentrations in HIV‐1–Infected Patients Receiving Combination TherapyThe Journal of Infectious Diseases, 1999
- Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudineThe Lancet, 1998
- Relationship between human immunodeficiency virus—associated dementia and viral load in cerebrospinal fluid and brainAnnals of Neurology, 1997
- The Effect on Human Immunodeficiency Virus Type 1 RNA Levels in Cerebrospinal Fluid after Initiation of Zidovudine or DidanosineThe Journal of Infectious Diseases, 1997
- Isolation of HTLV-III from Cerebrospinal Fluid and Neural Tissues of Patients with Neurologic Syndromes Related to the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1985